News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
737,295 Results
Type
Article (69694)
Company Profile (223)
Press Release (667378)
Section
Business (208310)
Career Advice (3353)
Deals (38747)
Drug Delivery (102)
Drug Development (84800)
Employer Resources (183)
FDA (17099)
Job Trends (16690)
News (361105)
Policy (37010)
Tag
Academia (2968)
Africa (1100)
Alabama (33)
Allergies (41)
Alliances (50958)
Alzheimer's disease (1192)
Antibody-drug conjugate (ADC) (59)
Approvals (17035)
Arizona (138)
Artificial intelligence (62)
Asia (44073)
Australia (7582)
Bankruptcy (371)
Best Places to Work (12086)
Biosimilars (62)
C2C Services and Suppliers (82848)
California (845)
Canada (650)
Cancer (211)
Career advice (2839)
CAR-T (45)
Cell therapy (83)
China (52)
Clinical research (65683)
Collaboration (67)
Colorado (37)
COVID-19 (2717)
Cystic fibrosis (74)
Diabetes (38)
Diagnostics (6403)
Diversity, equity & inclusion (43)
Drug pricing (64)
Earnings (81312)
Employer resources (153)
Europe (101522)
Events (112357)
FDA (17145)
Florida (107)
Funding (42)
Gene therapy (64)
GLP-1 (564)
Government (4946)
Healthcare (20543)
Hotbed/Location (487463)
Idaho (60)
Illinois (225)
Indiana (110)
Infectious disease (2732)
Inflammatory bowel disease (94)
Interviews (648)
IPO (17132)
Job creations (4641)
Job search strategy (2355)
Kansas (96)
Layoffs (439)
Legal (9105)
Liver cancer (57)
Lung cancer (48)
Maine (52)
Management (57)
Manufacturing (58)
Maryland (271)
Massachusetts (467)
Medical device (14144)
Medtech (14147)
Mergers & acquisitions (21296)
Metabolic disorders (194)
Neuroscience (1284)
New Jersey (64)
New York (85)
NextGen Class of 2024 (7392)
Non-profit (5032)
North Carolina (181)
Obesity (125)
Opinion (218)
Patents (38)
Peanut (37)
Pennsylvania (56)
People (58410)
Phase I (20229)
Phase II (28602)
Phase III (21798)
Podcasts (64)
Policy (41)
Postmarket research (3066)
Preclinical (8700)
Rare diseases (96)
Real estate (6458)
Recruiting (72)
Regulatory (23773)
Reports (33)
Research institute (2621)
Resumes & cover letters (532)
South America (1483)
Startups (3941)
Texas (91)
United States (3156)
Vaccines (496)
Washington State (117)
Weight loss (128)
Date
Today (13)
Last 7 days (525)
Last 30 days (1900)
Last 365 days (40718)
2024 (23060)
2023 (42554)
2022 (53926)
2021 (58720)
2020 (57663)
2019 (51310)
2018 (39092)
2017 (35768)
2016 (35438)
2015 (44076)
2014 (39633)
2013 (34283)
2012 (30066)
2011 (30656)
2010 (29100)
737,295 Results for "ac immune sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune SA announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024.
May 28, 2024
·
3 min read
Genetown
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda and AC Immune SA announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease.
May 13, 2024
·
12 min read
Business
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune SA, a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, reported results for the quarter ended March 31, 2024, and provided a corporate update.
May 13, 2024
·
9 min read
Business
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta plaques.
May 13, 2024
·
2 min read
·
Nick Paul Taylor
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune SA announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Lisbon, Portugal March 5-9, 2024.
February 22, 2024
·
5 min read
Business
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the year ended December 31, 2023, and provided a corporate update.
March 14, 2024
·
13 min read
Business
AC Immune SA Appoints New Chief Medical Officer
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced the appointment of Nuno Mendonça, MD.
July 26, 2023
·
5 min read
Press Releases
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024
·
6 min read
Drug Development
Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
Anokion SA today announced additional favorable safety and efficacy data from the company’s ongoing Phase 1b/2 clinical trial (ACeD-it) evaluating KAN-101 as a treatment for celiac disease.
May 20, 2024
·
3 min read
AC Immune Announces Pricing of Underwritten Offering of Common Shares - December 15, 2023
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share.
December 15, 2023
·
5 min read
1 of 73,730
Next
